πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

20 results for β€œMarker” Clear

  1. FRΞ± peptide plus Adjuvant (GM-CSF)

    Marker Therapeutics

    Platinum Sensitive Ovarian Cancer

    phase 2 mab terminated

    1 trial

  2. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  3. Low dose FRΞ± vaccine

    Marker Therapeutics

    Breast Cancer

    phase 2 mab completed

    1 trial

  4. MT-401

    Marker Therapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  5. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  6. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  7. TPIV200

    Marker Therapeutics

    Ovarian Cancer

    phase 2 mab completed

    1 trial

  8. A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

    Pharm Research Associates (UK) Limited

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  9. HER-2/neu peptide vaccine

    Marker Therapeutics

    HER2-positive Breast Cancer

    phase 1 mab completed

    1 trial

  10. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  11. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  12. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  13. Biomarker

    United Therapeutics Europe Ltd

    Transplantation, Liver

    approved gene therapy terminated

    1 trial

  14. Blood ponction

    MAIA Biotechnology

    Alzheimer Blood Biomarkers

    other active

    1 trial

  15. Mail-in Urine Test for EDCs

    Marker Therapeutics

    Endocrine Disrupting Chemicals

    other completed

    1 trial

  16. Sitz-Markers

    United Therapeutics Europe Ltd

    Return of Bowel Function After Colon Surgery

    small molecule terminated

    1 trial

  17. Urinary EDC metabolite testing

    Marker Therapeutics

    Environmental Exposure

    other active

    1 trial

  18. Urinary EDC metabolite testing

    Marker Therapeutics

    Obesity &Amp;Amp;Amp; Overweight

    other active

    1 trial

  19. blood sampling

    Marker Therapeutics

    Screening for Colon Cancer

    other active

    1 trial

  20. blood sampling

    Marker Therapeutics

    Colorectal Cancer Screening

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources